Articles tagged with Gliomas
A veterinary neurologist is studying gliomas in dogs and people to develop more precisely targeted treatments. Researchers are using canine models to identify molecular similarities between human and animal gliomas.
Researchers used perfusion MRI to track changes in blood volume in patients with low-grade gliomas, finding that increased rCBV is an indicator of future malignant transformation. The study suggests that significant changes in rCBV represent an early warning sign of impending malignant transformation.
Researchers found a new chemotherapy regimen of irinotecan and cisplatin to be effective in treating childhood brainstem gliomas, with all six children showing significant tumor reduction. While the disease eventually progressed in three children, this is a promising breakthrough for a previously difficult-to-treat cancer.
Researchers discovered the p75NTR receptor plays a key role in glioma invasion, with expression sufficient to induce aggressive tumor growth. This finding highlights a previously unknown function of the receptor and suggests it may be a novel therapeutic target.
A clinical trial at UCSF Brain Tumor Research Center has shown promising results using the vitespen vaccine to stimulate the immune system to attack tumor cells. The vaccine, made from a patient's own tumor, induced a tumor-specific immune response in all 12 study patients.
Researchers have developed a new approach to treating gliomas, deadly brain tumors, by delivering radioactive iodine using a man-made version of scorpion venom as a carrier. The treatment targets glioma cells without affecting neighboring tissue or body organs and has shown promise in Phase I clinical trials.
Gliadel Wafer demonstrates long-term survival benefit for patients with high-grade malignant glioma, increasing median survival to 13.9 months from 11.6 months. The treatment also shows a significant reduction in risk of death over the study period, with a 27% lower risk compared to placebo.
A phase I study found that glioma patients who responded to erlotinib treatment had higher levels of EGFR expression and amplification. The level of phosphorylated PKB/Akt was also associated with response to erlotinib, as well as time to progression.
The study found significant variations in treatment practices for patients with malignant glioma, including differences in the use of radiation therapy, chemotherapy, and antidepressants. These variations were associated with differences in survival rates, highlighting the need for further investigation and potential improvements to tr...
Researchers found that new blood vessels and immune system cells are essential to tumor formation, making them promising drug targets; however, brain images used for diagnosis may not be informative.
Researchers at Cedars-Sinai Medical Center have discovered a mechanism by which brain tumors can evade the immune system, leading to impaired cellular immunity in patients with glioma. By blocking COX-2 expression, the study found that tumor-killing T cell responses can be restored, offering new potential treatments for brain tumors.
Cedars-Sinai researchers found that laminin-8 expression is linked to tumor aggressiveness and patient outcomes. High levels of laminin-8 are associated with shorter survival times and increased risk of tumor recurrence.
Researchers found that blocking laminin-8 gene expression significantly reduced glioma cells' ability to invade neighboring tissue. The study supports the hypothesis that laminin-8 is involved in tumor spread and suggests a potential target for intervention strategies.
A large-scale study of 560 patients with malignant gliomas suggests that surgical resection is a critical factor in improving survival rates and quality of life. The study found that younger, more active patients tend to benefit more from aggressive treatment, while age and overall health also play significant roles.
Researchers found that intracranial gliomas damage the thymus, weakening T cells and preventing a large-scale attack on the tumor. The study suggests that glucocorticoids produced by the adrenal glands contribute to this effect, and highlights the importance of recent thymic emigrant T cells in anti-glioma immunity.
A study by the University of Texas M. D. Anderson Cancer Center reveals a strong correlation between the loss of AP-2( transcription factor and the progression of different human gliomas. The findings suggest that this gene acts as a tumor suppressor, controlling various genes involved in cell proliferation and invasion.
Systematic review and meta-analysis of 12 randomised trials shows a 6% increase in one-year survival for patients receiving chemotherapy with radiotherapy compared to those receiving radiotherapy alone. Patients also experience a two-month improvement in average survival time.
Researchers used genetic tools to create mouse models of gliomas, revealing that the timing of PDGF expression can determine glioma characteristics. These findings suggest that drugs promoting glial cell differentiation may be effective for low-grade gliomas.
Scientists at Cedars-Sinai Medical Center used gene array technology to analyze thousands of genes in malignant brain tumor samples. They identified a critical step in the development of glioblastoma multiforme, which may improve patient prognosis and lead to effective therapies.